VCEDA Telehealth Fund

This funding opportunity is designed to support research in understanding how to engineer intrinsic characteristics of stem cell-derived islet cell products that can result in improved cell replacement therapy outcomes. Unlike cadaveric human islets, stem cell-derived islet cell products are generated from well-defined and highly controlled cell bank sources. Their banking, manufacturing, and quality control processes can be used to instill optimized cell characteristics resulting in more resilient and durable graft viability and function. This funding opportunity aims to stimulate studies on targets and pathways amenable to such engineering approaches and to encourage preclinical testing and validation of such strategies.This NOFO is associated with the Special Diabetes Program (https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program) which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks.

The purpose of this Notice of Funding Opportunity (NOFO) is to invite Small Research Grant (R21) applications that propose to study the ethical, legal, and social implications (ELSI) of human genetics and genomics. Applications may propose studies using either single or mixed methods. Direct involvement of key stakeholders where appropriate is encouraged. These applications should be for small research projects, such as those that involve single investigators. Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues. This mechanism can also be used for the collection of preliminary data and the secondary analysis of existing data.

This micro-grant program from Start.Pivot.Grow is open to businesses that have been in operation for at least two years, employ one-two people and generate annual revenue of at least $50,000. Grants of $2,500 are offered each quarter and applications are accepted on a rolling basis.

Purpose: The Orphan Site Cleanup Fund (OSCF) is a grant program providing financial assistance to eligible applicants for the cleanup of sites contaminated by leaking petroleum underground storage tanks where there is no financially responsible party, and the applicant is not an eligible claimant to the UST Cleanup Fund. The maximum amount of grant monies available for an eligible occurrence is $1 million. Description: Grants provide funding for response actions that characterize, assess, andinvestigate an unauthorized release from petroleum USTs. These actions include apreliminary site assessment, soil and groundwater investigations, and preparation of a corrective action plan in accordance with California Code of Regulations, Title 23, Chapter 16, Article 11. Grants may also provide funding for UST system removal, petroleum product removal and soil excavation, not to exceed 500 cubic yards at the eligible site. Grants also provide funding for response actions that carry out cleanup activities,implement a corrective action plans, and perform verification monitoring in accordance with California Code of Regulations, Title 23, Chapter 16, Article 11. If a corrective action plan is required, the State Water Board cannot award a cleanup grant until the applicant demonstrates the corrective action plan is complete and approved by the regulatory agency. However, the applicant may apply for a cleanup grant before completion and approval of the corrective action plan. Note that only the current property owner is eligible for a Cleanup Grant.

The Indiana Economic Development Corporation provides a state grant match to Indiana companies that have received a Phase I or II award through a federal Small Business Innovation Research (SBIR) or Small Business Technology Transfer (STTR) grant program. The maximum award amount is $50,000 for Phase I and $75,000 for Phase II.